Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation

NCT02723591 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT02723591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02723591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Phase 4
Overall status
Completed
Start date
September 9, 2016
Completion date
June 14, 2019
Enrollment
599 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation